{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:06:26Z","timestamp":1790175986275,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010905","name":"Major Research Plan","doi-asserted-by":"publisher","award":["81672542"],"award-info":[{"award-number":["81672542"]}],"id":[{"id":"10.13039\/501100010905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","award":["81402572"],"award-info":[{"award-number":["81402572"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10637-019-00839-8","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T15:41:14Z","timestamp":1567006874000},"page":"956-966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Xi\u2019an","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9029-9904","authenticated-orcid":false,"given":"Lan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"issue":"5","key":"839_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277\u2013285. https:\/\/doi.org\/10.1038\/nrurol.2010.47","journal-title":"Nat Rev Urol"},{"issue":"2 Pt 2","key":"839_CR2","doi-asserted-by":"publisher","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","volume":"13","author":"WG Kaelin Jr","year":"2007","unstructured":"Kaelin WG Jr (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13(2 Pt 2):680s\u2013684s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1865","journal-title":"Clin Cancer Res"},{"issue":"7","key":"839_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ctrv.2012.12.015","volume":"39","author":"SK Pal","year":"2013","unstructured":"Pal SK, Quinn DI (2013) Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 39(7):709\u2013719. https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.015","journal-title":"Cancer Treat Rev"},{"key":"839_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2407-13-170","volume":"13","author":"TM Cardillo","year":"2013","unstructured":"Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH (2013) Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer 13:170. https:\/\/doi.org\/10.1186\/1471-2407-13-170","journal-title":"BMC Cancer"},{"issue":"3","key":"839_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ijc.11228","volume":"106","author":"Y Deng","year":"2003","unstructured":"Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, Han H, Nie X, Li Q, Kung HF, Leung SY, Lin MC (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106(3):342\u2013347. https:\/\/doi.org\/10.1002\/ijc.11228","journal-title":"Int J Cancer"},{"issue":"1","key":"839_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00441-005-0137-5","volume":"325","author":"XL Hu","year":"2006","unstructured":"Hu XL, Liu XP, Deng YC, Lin SX, Wu L, Zhang J, Wang LF, Wang XB, Li X, Shen L, Zhang YQ, Yao LB (2006) Expression analysis of the NDRG2 gene in mouse embryonic and adult tissues. Cell Tissue Res 325(1):67\u201376. https:\/\/doi.org\/10.1007\/s00441-005-0137-5","journal-title":"Cell Tissue Res"},{"issue":"7","key":"839_CR7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1248\/bpb.31.1316","volume":"31","author":"J Ma","year":"2008","unstructured":"Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang X, Zhang W, Zhao H, Yao L (2008) Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 31(7):1316\u20131320","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"839_CR8","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1245\/s10434-011-2204-3","volume":"19","author":"ZL Liang","year":"2012","unstructured":"Liang ZL, Kang K, Yoon S, Huang SM, Lim JS, Kim JM, Lim JS, Lee HJ (2012) NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. Ann Surg Oncol 19(8):2763\u20132772. https:\/\/doi.org\/10.1245\/s10434-011-2204-3","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"839_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12013-014-9961-0","volume":"70","author":"Z Wu","year":"2014","unstructured":"Wu Z, Liao H, Su J, Yang L, Chi Z, OuYang X (2014) Adenovirus-mediated NDRG2 inhibits the proliferation of human renal cell carcinoma cell line OS-RC-2 in vitro. Cell Biochem Biophys 70(1):593\u2013600. https:\/\/doi.org\/10.1007\/s12013-014-9961-0","journal-title":"Cell Biochem Biophys"},{"issue":"5","key":"839_CR10","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1007\/s12032-012-0265-1","volume":"29","author":"JJ Ma","year":"2012","unstructured":"Ma JJ, Kong LM, Liao CG, Jiang X, Wang Y, Bao TY (2012) Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion. Med Oncol 29(5):3306\u20133313. https:\/\/doi.org\/10.1007\/s12032-012-0265-1","journal-title":"Med Oncol"},{"issue":"5","key":"839_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"28","key":"839_CR12","doi-asserted-by":"publisher","first-page":"26161","DOI":"10.18632\/oncotarget.4544","volume":"6","author":"X Xu","year":"2015","unstructured":"Xu X, Li J, Sun X, Guo Y, Chu D, Wei L, Li X, Yang G, Liu X, Yao L, Zhang J, Shen L (2015) Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression. Oncotarget 6(28):26161\u201326176. https:\/\/doi.org\/10.18632\/oncotarget.4544","journal-title":"Oncotarget"},{"issue":"2","key":"839_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.bbrc.2017.01.018","volume":"483","author":"T Pan","year":"2017","unstructured":"Pan T, Zhang M, Zhang F, Yan G, Ru Y, Wang Q, Zhang Y, Wei X, Xu X, Shen L, Zhang J, Wu K, Yao L, Li X (2017) NDRG2 overexpression suppresses hepatoma cells survival during metabolic stress through disturbing the activation of fatty acid oxidation. Biochem Biophys Res Commun 483(2):860\u2013866. https:\/\/doi.org\/10.1016\/j.bbrc.2017.01.018","journal-title":"Biochem Biophys Res Commun"},{"key":"839_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1476-4598-10-90","volume":"10","author":"D Roulin","year":"2011","unstructured":"Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10:90. https:\/\/doi.org\/10.1186\/1476-4598-10-90","journal-title":"Mol Cancer"},{"issue":"8","key":"839_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/onc.2009.403","volume":"29","author":"V Ramakrishnan","year":"2010","unstructured":"Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S (2010) Sorafenib, a dual Raf kinase\/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 29(8):1190\u20131202. https:\/\/doi.org\/10.1038\/onc.2009.403","journal-title":"Oncogene"},{"issue":"11","key":"839_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia Z, Gavathiotis E, Poulikakos PI (2017) New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer 17(11):676\u2013691. https:\/\/doi.org\/10.1038\/nrc.2017.79","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 9","key":"839_CR17","doi-asserted-by":"publisher","first-page":"ix98","DOI":"10.1093\/annonc\/mdm303","volume":"18","author":"PH De Mulder","year":"2007","unstructured":"De Mulder PH (2007) Targeted therapy in metastatic renal cell carcinoma. Ann Oncol 18(Suppl 9):ix98\u2013ix102. https:\/\/doi.org\/10.1093\/annonc\/mdm303","journal-title":"Ann Oncol"},{"issue":"1","key":"839_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2013.02.006","volume":"88","author":"P Barthelemy","year":"2013","unstructured":"Barthelemy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B (2013) mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit Rev Oncol Hematol 88(1):42\u201356. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.02.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"839_CR19","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1038\/ncomms4393","volume":"5","author":"S Nakahata","year":"2014","unstructured":"Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K (2014) Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun 5:3393. https:\/\/doi.org\/10.1038\/ncomms4393","journal-title":"Nat Commun"},{"issue":"6","key":"839_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cmet.2014.09.013","volume":"20","author":"DG Hardie","year":"2014","unstructured":"Hardie DG (2014) AMPK--sensing energy while talking to other signaling pathways. Cell Metab 20(6):939\u2013952. https:\/\/doi.org\/10.1016\/j.cmet.2014.09.013","journal-title":"Cell Metab"},{"issue":"1","key":"839_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20(1):51\u201356. https:\/\/doi.org\/10.1016\/j.gde.2009.10.009","journal-title":"Curr Opin Genet Dev"},{"key":"839_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/82_2017_6","volume":"407","author":"M Aoki","year":"2017","unstructured":"Aoki M, Fujishita T (2017) Oncogenic roles of the PI3K\/AKT\/mTOR Axis. Curr Top Microbiol Immunol 407:153\u2013189. https:\/\/doi.org\/10.1007\/82_2017_6","journal-title":"Curr Top Microbiol Immunol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00839-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:39:43Z","timestamp":1678509583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00839-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00839-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments involved in this study were approved by both the Institutional Review Boards of The Fourth Military Medical University and the Ethics Committee of the above hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient provided a written consent prior to the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}